Novo Nordisk (NVO)
(Delayed Data from NYSE)
$131.54 USD
+1.55 (1.19%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $131.58 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVO 131.54 +1.55(1.19%)
Will NVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Other News for NVO
7 Sorry Biotech Stocks Set to Make Investors Sad
Hims & Hers appoints Kundefinedre Schultz to board of directors
The Top 20 Highest Quality Companies In The World
Kamala Harris' potential impact on health care stocks
Here are Big Pharma’s leading blockbuster makers